Merus (MRUS) Competitors $41.60 -1.61 (-3.73%) Closing price 05/22/2025 04:00 PM EasternExtended Trading$47.25 +5.65 (+13.58%) As of 05/22/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MRUS vs. VTRS, MRNA, ASND, QGEN, ROIV, RVMD, ELAN, BPMC, BBIO, and VRNAShould you be buying Merus stock or one of its competitors? The main competitors of Merus include Viatris (VTRS), Moderna (MRNA), Ascendis Pharma A/S (ASND), Qiagen (QGEN), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Elanco Animal Health (ELAN), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), and Verona Pharma (VRNA). These companies are all part of the "pharmaceutical products" industry. Merus vs. Viatris Moderna Ascendis Pharma A/S Qiagen Roivant Sciences Revolution Medicines Elanco Animal Health Blueprint Medicines BridgeBio Pharma Verona Pharma Merus (NASDAQ:MRUS) and Viatris (NASDAQ:VTRS) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation, dividends and community ranking. Do insiders and institutionals hold more shares of MRUS or VTRS? 96.1% of Merus shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 4.6% of Merus shares are held by company insiders. Comparatively, 0.1% of Viatris shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media favor MRUS or VTRS? In the previous week, Viatris had 15 more articles in the media than Merus. MarketBeat recorded 32 mentions for Viatris and 17 mentions for Merus. Merus' average media sentiment score of 1.13 beat Viatris' score of -0.02 indicating that Merus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Merus 11 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viatris 0 Very Positive mention(s) 2 Positive mention(s) 26 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Which has higher valuation & earnings, MRUS or VTRS? Viatris has higher revenue and earnings than Merus. Merus is trading at a lower price-to-earnings ratio than Viatris, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMerus$54.73M52.61-$154.94M-$4.08-10.20Viatris$14.33B0.70$54.70M-$3.17-2.68 Does the MarketBeat Community favor MRUS or VTRS? Merus received 343 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 67.90% of users gave Merus an outperform vote while only 34.85% of users gave Viatris an outperform vote. CompanyUnderperformOutperformMerusOutperform Votes36667.90% Underperform Votes17332.10% ViatrisOutperform Votes2334.85% Underperform Votes4365.15% Is MRUS or VTRS more profitable? Viatris has a net margin of -5.87% compared to Merus' net margin of -680.61%. Viatris' return on equity of 16.46% beat Merus' return on equity.Company Net Margins Return on Equity Return on Assets Merus-680.61% -38.89% -31.16% Viatris -5.87%16.46%7.09% Which has more volatility and risk, MRUS or VTRS? Merus has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, Viatris has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500. Do analysts recommend MRUS or VTRS? Merus currently has a consensus price target of $84.54, indicating a potential upside of 103.22%. Viatris has a consensus price target of $10.50, indicating a potential upside of 23.53%. Given Merus' stronger consensus rating and higher possible upside, analysts clearly believe Merus is more favorable than Viatris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Merus 0 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 2 Strong Buy rating(s) 3.13Viatris 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75 SummaryMerus beats Viatris on 12 of the 19 factors compared between the two stocks. Get Merus News Delivered to You Automatically Sign up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRUS vs. The Competition Export to ExcelMetricMerusPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.88B$6.47B$5.33B$8.39BDividend YieldN/A2.64%5.21%4.11%P/E Ratio-10.539.0626.7119.71Price / Sales52.61251.51386.08120.53Price / CashN/A65.8538.2534.62Price / Book6.746.456.774.50Net Income-$154.94M$143.98M$3.23B$248.22M7 Day Performance0.10%0.38%0.48%-0.78%1 Month Performance-0.55%2.14%9.10%11.53%1 Year Performance-5.60%-0.33%18.56%8.99% Merus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRUSMerus3.2298 of 5 stars$41.60-3.7%$84.54+103.2%-4.1%$2.88B$54.73M-10.5337News CoveragePositive NewsAnalyst ForecastOptions VolumeHigh Trading VolumeVTRSViatris1.8962 of 5 stars$8.76-0.9%$10.50+19.9%-21.8%$10.28B$14.33B-11.8437,000Trending NewsMRNAModerna4.4407 of 5 stars$26.39+6.2%$53.95+104.4%-83.6%$10.21B$3.14B-2.843,900Trending NewsAnalyst ForecastGap UpHigh Trading VolumeASNDAscendis Pharma A/S3.3776 of 5 stars$160.33+1.7%$216.07+34.8%+22.0%$9.78B$368.70M-22.58640QGENQiagen3.9804 of 5 stars$42.77+0.3%$48.42+13.2%+0.1%$9.51B$2.00B119.096,030Positive NewsROIVRoivant Sciences2.1187 of 5 stars$10.84+0.5%$17.50+61.4%-3.1%$7.73B$122.59M-72.26860Positive NewsUpcoming EarningsInsider TradeRVMDRevolution Medicines4.3594 of 5 stars$39.93+1.0%$67.08+68.0%-2.4%$7.44B$742,000.00-11.12250Positive NewsELANElanco Animal Health3.2246 of 5 stars$13.24+2.5%$15.17+14.6%-25.1%$6.58B$4.43B33.109,800Gap UpBPMCBlueprint Medicines2.6082 of 5 stars$101.21-0.5%$126.56+25.0%-2.3%$6.54B$562.12M-93.71640Positive NewsInsider TradeBBIOBridgeBio Pharma4.5993 of 5 stars$33.69-0.4%$57.09+69.5%+12.6%$6.40B$127.42M-11.82400Insider TradeVRNAVerona Pharma2.6573 of 5 stars$72.58+1.8%$81.50+12.3%+476.9%$5.88B$118.54M-37.8030Positive NewsGap Down Related Companies and Tools Related Companies Viatris Competitors Moderna Competitors Ascendis Pharma A/S Competitors Qiagen Competitors Roivant Sciences Competitors Revolution Medicines Competitors Elanco Animal Health Competitors Blueprint Medicines Competitors BridgeBio Pharma Competitors Verona Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRUS) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merus Please log in to your account or sign up in order to add this asset to your watchlist. Share Merus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MRUS Stock Free MRUS Stock Alerts